Search Results
228 items found for "Omass Therapeutics"
- Targeting the M1 muscarinic receptor in neurodegenerative disease
the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic
- Dr. Juan José Fung - Dr. GPCR Podcast
Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.
- Chemokine receptor-targeted drug discovery: progress and challenges
The therapeutic approaches mainly include small molecule inhibitors, as well as monoclonal antibodies frequency of administration are particularly rigorous for this class, as the majority of potential therapeutic Overall, the future potential lies in using different therapeutic modalities to modulate the stromal
- InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
prediction of first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic
- Exploring the Breakthroughs in GPCR Research
GPCRs remain one of the most prolific and fertile therapeutic drug targets. signalling bias and allosteric modulation Structural and Molecular Insights into GPCR Function Structural Mass
- Molecular insights into psychedelic drug action
actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic
- Molecular targets of psychedelic-induced plasticity
toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Modalities A quick revision of how β-adrenergic receptors work and how their antagonists can achieve therapeutic Galien USA ‘Best Startup’ Award: Pioneering GPCR-Driven Immunotherapies in Cancer Treatment Structure Therapeutics
- Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild trauma
This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model
- G protein-coupled receptor signaling: transducers and effectors
physiological functions and in a large number of Food and Drug Administration (FDA)-approved drugs as therapeutic
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
combination of Steyaert’s fundamental research and his ability to apply the research to the development of therapeutic
- G protein-coupled receptor interactions and modification of signalling involving the ghrelin ...
The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential as a therapeutic Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH)
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
These advances have paved the way for development of novel ligands for different therapeutic applications
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics
- 📰 GPCR Weekly News, May 6 to 12, 2024
Stay tuned for our next symposium on GPCRs as Therapeutics Targets on October 11th, 2024. Post-COVID-Vaccination Syndrome With Anti-G-Protein-Coupled Receptor (GPCR) Antibodies Treated With Therapeutic neutrophil biology: inflammation, resolution and beyond Exploring GPCR signaling pathway networks as cancer therapeutic
- Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell...
2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic
- Viral G Protein-Coupled Receptors Encoded by β- and γ-Herpesviruses
Finally, we briefly discuss the therapeutic targeting of vGPCRs as future treatment of acute and chronic
- Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic
- 📰 GPCR Weekly News, April 1 to 7, 2024
signaling in humoral immunity Industry News Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics Financial Resultsand Confirms Its 2024 Outlook Sosei Heptares officially changed their name to Nxera Domain Therapeutics
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development of therapeutic
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
receptor subfamily, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
From omics to epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic complexes with MolBoolean Screening GPR75 Modulators Using Medium-Throughput Reporter Gene Assay GPCR Therapeutics
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted therapeutics
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
- Chronic itch: emerging treatments following new research concepts
itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
Ottawa, Ontario, Canada, Nov. 30, 2021 -- Orion Biotechnology , a clinical stage company unlocking the therapeutic
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Industry News Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover SMILES-based de novo molecular generation with curriculum and deep reinforcement learning Structure Therapeutics